Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Tuspetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    clonoSEQ® MRD Testing Integrated into OncoEMR®
    clonoSEQ® MRD Testing Integrated into OncoEMR®

    01 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/01/3108232/0/en/Adaptive-Biotechnologies-and-Flatiron-Health-Announce-Integration-of-clonoSEQ-MRD-Testing-into-OncoEMR.html

    GLOBENEWSWIRE
    01 Jul 2025
    Share Share
    Aptose and Hanmi's New Loan Agreement for Tuspetinib in AML
    Aptose and Hanmi's New Loan Agreement for Tuspetinib in AML

    20 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/20/3102654/35575/en/Aptose-and-Hanmi-Enter-New-Loan-Agreement-to-Advance-Development-of-Tuspetinib-in-Triplet-Therapy-for-AML.html

    GLOBENEWSWIRE
    20 Jun 2025
    Share Share
    Aptose to Present Tuspetinib Data at 2025 EHA Congress
    Aptose to Present Tuspetinib Data at 2025 EHA Congress

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081434/35575/en/Aptose-Selected-for-Prestigious-Oral-Presentation-of-Data-from-TUSCANY-Phase-1-2-Clinical-Trial-of-Tuspetinib-Triplet-Therapy-in-Newly-Diagnosed-AML-at-the-2025-EHA-Congress.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Aptose updates Tuspetinib-based triple drug therapy in AML trial
    Aptose updates Tuspetinib-based triple drug therapy in AML trial

    05 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/05/3073937/35575/en/Aptose-Provides-Clinical-Update-for-the-Tuspetinib-based-Triple-Drug-Frontline-Therapy-in-Newly-Diagnosed-AML-Patients-from-the-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    05 May 2025
    Share Share
    Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
    Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053375/35575/en/Aptose-Common-Shares-to-Delist-from-Nasdaq-as-of-April-2-2025.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Aptose Reports Year End 2024 Results and Corporate Highlights
    Aptose Reports Year End 2024 Results and Corporate Highlights

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051334/35575/en/Aptose-Reports-Year-End-2024-Results-and-Corporate-Highlights.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share